Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer

Oppenheimer initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX) in a research report report published on Monday, Marketbeat Ratings reports. The firm issued an outperform rating and a $10.00 target price on the stock.

A number of other research analysts have also weighed in on QNCX. D. Boral Capital reissued a “buy” rating and issued a $12.00 target price on shares of Quince Therapeutics in a report on Wednesday, February 5th. Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $9.60.

Quince Therapeutics Stock Up 1.4 %

QNCX opened at $1.40 on Monday. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $61.60 million, a PE ratio of -1.13 and a beta of 0.71. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The firm has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $1.44.

Hedge Funds Weigh In On Quince Therapeutics

Several hedge funds have recently added to or reduced their stakes in QNCX. Anfield Capital Management LLC bought a new position in Quince Therapeutics in the 4th quarter valued at $50,000. Virtu Financial LLC bought a new stake in Quince Therapeutics during the 4th quarter valued at about $55,000. Two Sigma Investments LP purchased a new stake in Quince Therapeutics in the 4th quarter valued at about $57,000. Northern Trust Corp grew its stake in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after acquiring an additional 16,501 shares in the last quarter. Finally, Scharf Investments LLC purchased a new position in shares of Quince Therapeutics during the fourth quarter worth approximately $170,000. 30.75% of the stock is currently owned by institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.